Eli Lilly and Company (NYSE:LLY) Stock Position Lowered by Brave Asset Management Inc.

Brave Asset Management Inc. lessened its position in Eli Lilly and Company (NYSE:LLY) by 6.5% in the 4th quarter, according to the company in its most recent filing with the SEC. The institutional investor owned 1,799 shares of the company’s stock after selling 126 shares during the quarter. Brave Asset Management Inc.’s holdings in Eli Lilly and Company were worth $1,049,000 as of its most recent filing with the SEC.

Several other hedge funds have also made changes to their positions in the company. JGP Wealth Management LLC lifted its position in Eli Lilly and Company by 0.9% in the 4th quarter. JGP Wealth Management LLC now owns 1,843 shares of the company’s stock worth $1,074,000 after buying an additional 16 shares in the last quarter. Cassia Capital Partners LLC lifted its position in Eli Lilly and Company by 1.8% in the 3rd quarter. Cassia Capital Partners LLC now owns 951 shares of the company’s stock worth $511,000 after buying an additional 17 shares in the last quarter. Walkner Condon Financial Advisors LLC lifted its position in Eli Lilly and Company by 2.8% in the 3rd quarter. Walkner Condon Financial Advisors LLC now owns 621 shares of the company’s stock worth $334,000 after buying an additional 17 shares in the last quarter. Patton Albertson Miller Group LLC lifted its position in Eli Lilly and Company by 2.8% in the 3rd quarter. Patton Albertson Miller Group LLC now owns 623 shares of the company’s stock worth $335,000 after buying an additional 17 shares in the last quarter. Finally, Valley Wealth Managers Inc. lifted its position in Eli Lilly and Company by 1.3% in the 3rd quarter. Valley Wealth Managers Inc. now owns 1,280 shares of the company’s stock worth $688,000 after buying an additional 17 shares in the last quarter. Hedge funds and other institutional investors own 82.53% of the company’s stock.

Eli Lilly and Company Stock Performance

NYSE LLY traded down $0.22 during midday trading on Thursday, hitting $777.96. The company had a trading volume of 3,185,016 shares, compared to its average volume of 3,236,305. The company has a quick ratio of 0.73, a current ratio of 0.94 and a debt-to-equity ratio of 1.69. The stock has a market cap of $739.19 billion, a price-to-earnings ratio of 134.13, a P/E/G ratio of 1.70 and a beta of 0.34. The firm has a fifty day simple moving average of $730.97 and a two-hundred day simple moving average of $637.01. Eli Lilly and Company has a fifty-two week low of $334.58 and a fifty-two week high of $800.78.

Eli Lilly and Company (NYSE:LLY) last posted its quarterly earnings results on Tuesday, February 6th. The company reported $2.49 earnings per share (EPS) for the quarter, topping the consensus estimate of $2.30 by $0.19. The company had revenue of $9.35 billion for the quarter, compared to analyst estimates of $8.95 billion. Eli Lilly and Company had a net margin of 15.36% and a return on equity of 51.22%. The business’s quarterly revenue was up 28.1% on a year-over-year basis. During the same period last year, the business posted $2.09 EPS. Equities analysts forecast that Eli Lilly and Company will post 12.42 earnings per share for the current fiscal year.

Insiders Place Their Bets

In other news, major shareholder Lilly Endowment Inc sold 34,538 shares of Eli Lilly and Company stock in a transaction dated Tuesday, January 9th. The shares were sold at an average price of $631.81, for a total transaction of $21,821,453.78. Following the sale, the insider now directly owns 99,719,884 shares in the company, valued at approximately $63,004,019,910.04. The sale was disclosed in a document filed with the SEC, which is available through this hyperlink. Insiders have sold 195,055 shares of company stock worth $125,254,657 in the last ninety days. Insiders own 0.13% of the company’s stock.

Wall Street Analysts Forecast Growth

A number of equities research analysts have issued reports on the stock. DZ Bank downgraded shares of Eli Lilly and Company from a “buy” rating to a “hold” rating and set a $820.00 target price for the company. in a research report on Wednesday, February 21st. Cantor Fitzgerald restated an “overweight” rating and set a $815.00 price target on shares of Eli Lilly and Company in a report on Tuesday, February 20th. Morgan Stanley raised their price target on shares of Eli Lilly and Company from $805.00 to $950.00 and gave the company an “overweight” rating in a report on Friday, February 16th. Wells Fargo & Company raised their price target on shares of Eli Lilly and Company from $700.00 to $825.00 and gave the company an “overweight” rating in a report on Tuesday, February 6th. Finally, BMO Capital Markets raised their price target on shares of Eli Lilly and Company from $710.00 to $865.00 and gave the company an “outperform” rating in a report on Wednesday, February 7th. Three investment analysts have rated the stock with a hold rating and seventeen have issued a buy rating to the company. Based on data from MarketBeat, the company presently has an average rating of “Moderate Buy” and a consensus price target of $689.52.

Eli Lilly and Company Company Profile

Eli Lilly and Company discovers, develops, and markets human pharmaceuticals worldwide. The company offers Basaglar, Humalog, Humalog Mix 75/25, Humalog U-100, Humalog U-200, Humalog Mix 50/50, insulin lispro, insulin lispro protamine, insulin lispro mix 75/25, Humulin, Humulin 70/30, Humulin N, Humulin R, and Humulin U-500 for diabetes; Jardiance, Mounjaro, and Trulicity for type 2 diabetes; and Zepbound for obesity.